title: Enhancing quality of life as a goal for anticancer therapeutics.
abstract: Translational cancer research requires a quality-of-life-driven agenda.
authors.affiliation: Syril D. Pettit is the Executive Director of the ILSI, Health and Environmental Sciences Institute (HESI), Washington, DC 20005, USA. Email: spettit@hesiglobal.orgSteven E. Lipshultz is Pediatrician-in-Chief of Children's Hospital of Michigan; Chair of Pediatrics, Wayne State University School of Medicine; President of University Pediatricians; and Interim Director of Children's Research Center of Michigan, Detroit, MI 48201, USA; and Editor-in-Chief, Cardio-Oncology.Charles S. Cleeland is McCullough Professor of Cancer Research, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.Samantha Roberts is Director of Scientific Affairs, Friends of Cancer Research, Washington, DC 20036, USA.Myrtle Davis is Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute, Bethesda, MD 20892, USA.Brian R. Berridge is Senior GSK Fellow and Head of Worldwide Animal Research Strategy, GlaxoSmithKline, King of Prussia, PA 19406, USA.Rebecca A. Kirch is Executive Vice President, Healthcare Quality and Value, National Patient Advocate Foundation, Washington, DC 20005, USA.
authors.forename: Syril D
authors.initials: SD
authors.lastname: Pettit
authors.affiliation: Syril D. Pettit is the Executive Director of the ILSI, Health and Environmental Sciences Institute (HESI), Washington, DC 20005, USA. Email: spettit@hesiglobal.orgSteven E. Lipshultz is Pediatrician-in-Chief of Children's Hospital of Michigan; Chair of Pediatrics, Wayne State University School of Medicine; President of University Pediatricians; and Interim Director of Children's Research Center of Michigan, Detroit, MI 48201, USA; and Editor-in-Chief, Cardio-Oncology.Charles S. Cleeland is McCullough Professor of Cancer Research, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.Samantha Roberts is Director of Scientific Affairs, Friends of Cancer Research, Washington, DC 20036, USA.Myrtle Davis is Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute, Bethesda, MD 20892, USA.Brian R. Berridge is Senior GSK Fellow and Head of Worldwide Animal Research Strategy, GlaxoSmithKline, King of Prussia, PA 19406, USA.Rebecca A. Kirch is Executive Vice President, Healthcare Quality and Value, National Patient Advocate Foundation, Washington, DC 20005, USA.
authors.forename: Steven E
authors.initials: SE
authors.lastname: Lipshultz
authors.affiliation: Syril D. Pettit is the Executive Director of the ILSI, Health and Environmental Sciences Institute (HESI), Washington, DC 20005, USA. Email: spettit@hesiglobal.orgSteven E. Lipshultz is Pediatrician-in-Chief of Children's Hospital of Michigan; Chair of Pediatrics, Wayne State University School of Medicine; President of University Pediatricians; and Interim Director of Children's Research Center of Michigan, Detroit, MI 48201, USA; and Editor-in-Chief, Cardio-Oncology.Charles S. Cleeland is McCullough Professor of Cancer Research, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.Samantha Roberts is Director of Scientific Affairs, Friends of Cancer Research, Washington, DC 20036, USA.Myrtle Davis is Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute, Bethesda, MD 20892, USA.Brian R. Berridge is Senior GSK Fellow and Head of Worldwide Animal Research Strategy, GlaxoSmithKline, King of Prussia, PA 19406, USA.Rebecca A. Kirch is Executive Vice President, Healthcare Quality and Value, National Patient Advocate Foundation, Washington, DC 20005, USA.
authors.forename: Charles S
authors.initials: CS
authors.lastname: Cleeland
authors.affiliation: Syril D. Pettit is the Executive Director of the ILSI, Health and Environmental Sciences Institute (HESI), Washington, DC 20005, USA. Email: spettit@hesiglobal.orgSteven E. Lipshultz is Pediatrician-in-Chief of Children's Hospital of Michigan; Chair of Pediatrics, Wayne State University School of Medicine; President of University Pediatricians; and Interim Director of Children's Research Center of Michigan, Detroit, MI 48201, USA; and Editor-in-Chief, Cardio-Oncology.Charles S. Cleeland is McCullough Professor of Cancer Research, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.Samantha Roberts is Director of Scientific Affairs, Friends of Cancer Research, Washington, DC 20036, USA.Myrtle Davis is Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute, Bethesda, MD 20892, USA.Brian R. Berridge is Senior GSK Fellow and Head of Worldwide Animal Research Strategy, GlaxoSmithKline, King of Prussia, PA 19406, USA.Rebecca A. Kirch is Executive Vice President, Healthcare Quality and Value, National Patient Advocate Foundation, Washington, DC 20005, USA.
authors.forename: Samantha
authors.initials: S
authors.lastname: Roberts
authors.affiliation: Syril D. Pettit is the Executive Director of the ILSI, Health and Environmental Sciences Institute (HESI), Washington, DC 20005, USA. Email: spettit@hesiglobal.orgSteven E. Lipshultz is Pediatrician-in-Chief of Children's Hospital of Michigan; Chair of Pediatrics, Wayne State University School of Medicine; President of University Pediatricians; and Interim Director of Children's Research Center of Michigan, Detroit, MI 48201, USA; and Editor-in-Chief, Cardio-Oncology.Charles S. Cleeland is McCullough Professor of Cancer Research, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.Samantha Roberts is Director of Scientific Affairs, Friends of Cancer Research, Washington, DC 20036, USA.Myrtle Davis is Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute, Bethesda, MD 20892, USA.Brian R. Berridge is Senior GSK Fellow and Head of Worldwide Animal Research Strategy, GlaxoSmithKline, King of Prussia, PA 19406, USA.Rebecca A. Kirch is Executive Vice President, Healthcare Quality and Value, National Patient Advocate Foundation, Washington, DC 20005, USA.
authors.forename: Myrtle
authors.initials: M
authors.lastname: Davis
authors.affiliation: Syril D. Pettit is the Executive Director of the ILSI, Health and Environmental Sciences Institute (HESI), Washington, DC 20005, USA. Email: spettit@hesiglobal.orgSteven E. Lipshultz is Pediatrician-in-Chief of Children's Hospital of Michigan; Chair of Pediatrics, Wayne State University School of Medicine; President of University Pediatricians; and Interim Director of Children's Research Center of Michigan, Detroit, MI 48201, USA; and Editor-in-Chief, Cardio-Oncology.Charles S. Cleeland is McCullough Professor of Cancer Research, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.Samantha Roberts is Director of Scientific Affairs, Friends of Cancer Research, Washington, DC 20036, USA.Myrtle Davis is Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute, Bethesda, MD 20892, USA.Brian R. Berridge is Senior GSK Fellow and Head of Worldwide Animal Research Strategy, GlaxoSmithKline, King of Prussia, PA 19406, USA.Rebecca A. Kirch is Executive Vice President, Healthcare Quality and Value, National Patient Advocate Foundation, Washington, DC 20005, USA.
authors.forename: Brian R
authors.initials: BR
authors.lastname: Berridge
authors.affiliation: Syril D. Pettit is the Executive Director of the ILSI, Health and Environmental Sciences Institute (HESI), Washington, DC 20005, USA. Email: spettit@hesiglobal.orgSteven E. Lipshultz is Pediatrician-in-Chief of Children's Hospital of Michigan; Chair of Pediatrics, Wayne State University School of Medicine; President of University Pediatricians; and Interim Director of Children's Research Center of Michigan, Detroit, MI 48201, USA; and Editor-in-Chief, Cardio-Oncology.Charles S. Cleeland is McCullough Professor of Cancer Research, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.Samantha Roberts is Director of Scientific Affairs, Friends of Cancer Research, Washington, DC 20036, USA.Myrtle Davis is Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute, Bethesda, MD 20892, USA.Brian R. Berridge is Senior GSK Fellow and Head of Worldwide Animal Research Strategy, GlaxoSmithKline, King of Prussia, PA 19406, USA.Rebecca A. Kirch is Executive Vice President, Healthcare Quality and Value, National Patient Advocate Foundation, Washington, DC 20005, USA.
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Kirch
mesh_terms: D006801:Humans; D054547:National Cancer Institute (U.S.); D009369:Neoplasms; D011788:Quality of Life; D057170:Translational Research, Biomedical / Q000379:methods*; D014481:United States